Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyvanse
Pharma
Takeda treads water despite loss of exclusivity on Vyvanse
Despite the recent loss of exclusivity on Takeda's ADHD med Vyvanse, the company's portfolio of newer products continues to hold the sales line.
Fraiser Kansteiner
Feb 1, 2024 1:56pm
Amid ADHD med shortage, AAM spotlights government restrictions
Nov 20, 2023 11:29am
Vyvanse, Keytruda-Lenvima, Adagene-ADC—Fierce Pharma Asia
Sep 1, 2023 8:50am
Amid shortage, FDA clears several generics of Takeda's Vyvanse
Aug 30, 2023 2:27pm
FDA Commissioner Robert Califf critiques low generic drug prices
Aug 22, 2023 10:05am
Takeda focuses on Qdenga as it braces for Vyvanse generics
Jul 27, 2023 1:38pm